Searched for
AUROBINDO PHARMA REVENUE GROWTH
Synopsys shares jump on robust growth outlook, OpenAI and AWS dealsSynopsys shares jumped 10% on Thursday after the chip-design software maker forecast fiscal 2027 revenue and profit above analysts' estimat...- In 2009, an entrepreneur invested $10,000 in a moving business; 13 years later, it generated $26 million in revenueBrian Slater started New City Moving in 2009 with $10,000 and one used truck. He built slowly, reinvesting what the business earned instead...
- Accenture sets annual revenue growth forecast at 3-6%, above estimatesAccenture anticipates full-year revenue growth between 3% and 6%, exceeding analysts' estimates of 3.9%. In the fourth quarter, Accenture r...
- GST collections remain strong, but faster import growth needs watching: Tax expertsIndia's GST collections remained strong, rising to Rs 2.04 lakh crore in September, however experts express concern over the wide gap in ta...
- Fortis, Apollo, other hospital stocks slump up to 10% in 2 days after SC questions steep markups. Buying opportunity?Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns o...
- IT companies forecast to post muted second quarterSector leader Tata Consultancy Services and its nearest rival, Infosys, are projected to report weak numbers for the three months ending Se...
- ChrysCapital to take minority stake in Linux laboratoriesLinux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involv...
- Cupid shares rally 16% in two sessions. What’s behind the sharp uptick in the multibagger stock?Cupid shares surged 7% after entering the Nifty Smallcap 250 index, extending gains to 16% in two sessions. The company has raised FY27 rev...
- FIIs dump telecom for 8th straight month, outflows cross Rs 32,000 crore. Are stocks set for rebound?Foreign portfolio investors have dumped Indian telecom stocks for the eighth consecutive month, pulling out over Rs 32,000 crore in CY26. H...
- CoinSwitch swings to profitability in FY26 as crypto platform’s revenue climbs 150% to Rs 324 croreCoinSwitch achieved profitability based on Adjusted EBITDA for FY26, with revenue growth of 150%. The company's revenue reached Rs 324.19 c...
- Anthropic’s Road to IPO: Funding, valuation, Claude growth and legal battlesAnthropic is preparing for a closely watched U.S. IPO after rapid growth in funding, valuation and revenue. The Claude maker faces legal an...
- Anupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platformAnupam Rasayan India Limited has finalised its acquisition of a controlling interest in Bliss GVS Pharma, marking a strategic expansion int...
- Sun Pharma, Aurobindo Pharma, other stocks in focus as Trump exempts India from 100% tariffs on some speciality drugsIndian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% ...
- Virtual pharma API firm HRV preparing for IPO, DRHP likely in H1 of 2027: SourcesHRV Pharma CEO Hari Kiran Chereddi says investing in capacity at partner facilities, exploring acquisitions for market access; forecasts Rs...
- Jagsonpal Pharma to acquire Group Pharma’s wellness portfolioJagsonpal Pharmaceuticals has signed a business transfer agreement to acquire the wellness portfolio of Group Pharmaceuticals. The acquisit...
- Pharma sector revenue to grow 11-13 pc in FY27 on strong exports, domestic demand: CrisilIndia's pharmaceutical sector is projected to grow at 11-13 percent this fiscal year due to export increases. The domestic market is also e...
- China's DeepSeek annualised revenue run rate hits $1 billion: ReportThe figure underscores the rapid growth of the AI company that shook the tech industry last year after its models challenged US assumptions...
- States' revenue growth to accelerate 9-11% as GST collections rise 16% in first five months: CrisilRevenue growth for 18 major Indian states is projected to accelerate to 9–11% in fiscal 2027, taking combined revenues past ₹44 lakh crore,...
- MF Tracker: HDFC Pharma & Healthcare Fund tops equity MFs at 25% in 1 year. Should investors chase the rally?HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time fra...
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...
Load More
